AVROBIO amends 8-K: no material charges from cystinosis gene therapy asset sale

Tectonic Therapeutic, Inc.

Amendment to prior 8-K (May 22, 2023) regarding sale of cystinosis gene therapy program.
Company had previously been unable to estimate related charges; now determines no material charges expected.
Asset sale includes all assets specifically related to the cystinosis gene therapy program.
No change to other disclosures in the original Form 8-K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.